Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288203 · ClinicalTrials.gov registry record · Phase 2
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
A Phase 2 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT07288203 is a Phase 2 study of Metastatic Melanoma and Unresectable Melanoma that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 100 participants, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (22% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT07288203, a Phase 2 study of Metastatic Melanoma and Unresectable Melanoma, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma
Conditions Studied
Interventions
- BIOLOGICAL Lifileucel
Study Locations (5)
Tennessee
- Sarah Cannon Research Institute - Nashville
Queensland
- Greenslopes Private Hospital - Greenslopes
Ontario, Canada
- Princess Margaret Cancer Centre - Toronto
Quebec, Canada
- Centre Hospitalier de l'Universite de Montreal - Montral
Other
- Royal Marsden Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-28 |
| Est. Completion | 2033-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07288203
The ClinicalTrials.gov registry entry for NCT07288203 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (22% higher). The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Lifileucel is the first listed.
NCT07288203 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Tennessee, Queensland, Ontario, Canada.
Frequently Asked Questions
What is clinical trial NCT07288203 about?
NCT07288203 is a clinical study titled "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma". This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma
What is the current status of trial NCT07288203?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-11-28. Estimated completion is 2033-12.
What conditions does trial NCT07288203 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma (Skin Cancer).
What interventions are being tested in trial NCT07288203?
The interventions under investigation include: Lifileucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT07288203?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288203 being conducted?
This trial has 5 study locations across Tennessee, Queensland, Ontario, Canada, Quebec, Canada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
-
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.